Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BVAC-B in HER2/neu Positive Gastric Cancer
NCT03425773Phase 1Completed
- Sponsor
- Cellid Co., Ltd.
- Start
- Feb 2018
- Primary completion
- May 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BVAC-B in gastric cancer (GC), sponsored by Cellid Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 7 months and Incidence of Serious Adverse Events at 14 weeks. Started Feb 2018; status: completed.
02
Drugs
BVAC-B
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03425773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425773.